Jones Trading Reaffirms “Hold” Rating for Oncolytics Biotech (NASDAQ:ONCY)

Oncolytics Biotech (NASDAQ:ONCY)‘s stock had its “hold” rating reaffirmed by analysts at Jones Trading in a research report issued to clients and investors on Friday,Benzinga reports.

ONCY has been the subject of several other reports. Royal Bank of Canada reduced their price target on Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating for the company in a research report on Monday, March 10th. Maxim Group reduced their target price on Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating for the company in a research note on Monday, March 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Oncolytics Biotech in a research note on Monday, March 10th. One analyst has rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $4.33.

Oncolytics Biotech Stock Performance

Shares of NASDAQ ONCY opened at $0.47 on Friday. The stock has a 50 day moving average price of $0.56 and a 200 day moving average price of $0.76. Oncolytics Biotech has a 52 week low of $0.45 and a 52 week high of $1.53. The stock has a market capitalization of $40.41 million, a PE ratio of -1.73 and a beta of 1.00.

Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03. As a group, research analysts forecast that Oncolytics Biotech will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in shares of Oncolytics Biotech by 59.6% during the 4th quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after acquiring an additional 24,997 shares during the period. Virtu Financial LLC acquired a new stake in Oncolytics Biotech during the 4th quarter worth approximately $90,000. National Bank of Canada FI lifted its holdings in Oncolytics Biotech by 199.6% during the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after purchasing an additional 42,955 shares during the last quarter. Finally, Vantage Point Financial LLC acquired a new stake in Oncolytics Biotech during the 4th quarter worth approximately $27,000. 6.82% of the stock is currently owned by institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.